Business Context and Reporting Period
Zentalis Pharmaceuticals, Inc. (ZNTL) filed a Form 8-K on May 12, 2026, to announce financial results for the quarter ended March 31, 2026. The filing also notes upcoming investor presentations regarding these results.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are referenced as being contained in the press release (Exhibit 99.1) and corporate presentation (Exhibit 99.2), which are incorporated by reference but not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that the Company announced its financial results for the quarter ended March 31, 2026.
Guidance, Outlook, and Risks
Management plans to present business updates and financial information at conferences and meetings with investors and analysts beginning May 12, 2026. The filing explicitly states that the information in Items 2.02 and 7.01, including the exhibits, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2026 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines and operational milestones.
- Verify the Company's cash runway and burn rate as disclosed in the referenced exhibits.
- Confirm any new guidance or forward-looking statements made during the May 12, 2026, investor presentations.